BIOCYTOGEN PHARMA. H YC1 (I54) - Net Assets
Based on the latest financial reports, BIOCYTOGEN PHARMA. H YC1 (I54) has net assets worth €2.18 Billion EUR (≈ $2.55 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.72 Billion ≈ $4.35 Billion USD) and total liabilities (€1.54 Billion ≈ $1.81 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore I54 cash flow metrics to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.18 Billion |
| % of Total Assets | 58.52% |
| Annual Growth Rate | 14.87% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 75.24 |
BIOCYTOGEN PHARMA. H YC1 - Net Assets Trend (2021–2025)
This chart illustrates how BIOCYTOGEN PHARMA. H YC1's net assets have evolved over time, based on quarterly financial data. Also explore I54 total asset value for the complete picture of this company's asset base.
Annual Net Assets for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
The table below shows the annual net assets of BIOCYTOGEN PHARMA. H YC1 from 2021 to 2025. For live valuation and market cap data, see BIOCYTOGEN PHARMA. H YC1 (I54) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €2.18 Billion ≈ $2.55 Billion |
+159.89% |
| 2024-12-31 | €838.60 Million ≈ $980.41 Million |
+6.09% |
| 2023-12-31 | €790.44 Million ≈ $924.10 Million |
-31.32% |
| 2022-12-31 | €1.15 Billion ≈ $1.35 Billion |
-8.08% |
| 2021-12-31 | €1.25 Billion ≈ $1.46 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to BIOCYTOGEN PHARMA. H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 77108900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.75 Billion | 172.34% |
| Total Equity | €2.17 Billion | 100.00% |
BIOCYTOGEN PHARMA. H YC1 Competitors by Market Cap
The table below lists competitors of BIOCYTOGEN PHARMA. H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Fengshangshiji Culture Medi
SHE:300860
|
$703.19 Million |
|
Jinzai Food Group Co Ltd
SHE:003000
|
$703.35 Million |
|
Criteo S.A
F:CI5A
|
$703.42 Million |
|
Jiangsu Province Commun
SHG:603018
|
$703.43 Million |
|
Mega First Corporation Bhd
KLSE:3069
|
$702.66 Million |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
$702.62 Million |
|
Shenmao Technology Inc
TW:3305
|
$702.56 Million |
|
Ningxia Xinri Hengli Steel Wire Rope Co Ltd
SHG:600165
|
$702.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BIOCYTOGEN PHARMA. H YC1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 834,056,000 to 2,174,909,000, a change of 1,340,853,000 (160.8%).
- Net income of 173,199,000 contributed positively to equity growth.
- Share repurchases of 18,074,000 reduced equity.
- New share issuances of 1,168,800,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €173.20 Million | +7.96% |
| Share Repurchases | €18.07 Million | -0.83% |
| Share Issuances | €1.17 Billion | +53.74% |
| Other Changes | €16.93 Million | +0.78% |
| Total Change | €- | 160.76% |
Book Value vs Market Value Analysis
This analysis compares BIOCYTOGEN PHARMA. H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.78x to 1.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.14 | €5.60 | x |
| 2022-12-31 | €2.87 | €5.60 | x |
| 2023-12-31 | €1.97 | €5.60 | x |
| 2024-12-31 | €2.10 | €5.60 | x |
| 2025-12-31 | €4.90 | €5.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BIOCYTOGEN PHARMA. H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.96%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.56%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.71x
- Recent ROE (7.96%) is above the historical average (-26.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -43.74% | -153.88% | 0.15x | 1.85x | €-670.30 Million |
| 2022 | -52.51% | -112.75% | 0.19x | 2.44x | €-716.57 Million |
| 2023 | -48.73% | -53.42% | 0.29x | 3.12x | €-461.54 Million |
| 2024 | 4.02% | 3.42% | 0.41x | 2.90x | €-49.86 Million |
| 2025 | 7.96% | 12.56% | 0.37x | 1.71x | €-44.29 Million |
Industry Comparison
This section compares BIOCYTOGEN PHARMA. H YC1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $223,512,703
- Average return on equity (ROE) among peers: -29.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BIOCYTOGEN PHARMA. H YC1 (I54) | €2.18 Billion | -43.74% | 0.71x | $702.88 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $212.27 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $1.82 Billion |
| BioNTech SE (22UA) | $31.86 Million | 0.00% | 11.24x | $20.05 Billion |
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides th… Read more